Gynecological Cancer
21
5
5
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 21 trials
100.0%
+13.5% vs benchmark
5%
1 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (21)
Perioperative Immunonutrition Under Enhanced Recovery After Surgery
Evaluate the Effectiveness of the Mobile Instant Messaging Intervention
Genomic Investigation of Unusual Responders
Laparoscopic Surgical Systems for Gynecological and Remote Surgical Treatment.
Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.
Supplemental High Flow Oxygen to Reduce Infections in Obese Gynecological Cancer Patients
Breathing Exercise Application in Patients With Gynecological Cancer.
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Investigation of the Effects of Online Education Application on Gynecological Cancer Patients Receiving Chemotherapy
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study
The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19
The Effectiveness of Anti-resistance Exercise on Lower Limb Lymphoedema Among Gynecological Cancer
A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
Intraoperative Music Therapy in Gynecological Oncology
Low-Intensity CBT for Gynaecological Cancer Survivors
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Recovery and Analgesia After Surgery for Gynecological Cancer
Laser Therapy Following Radiotherapy for Gynecological Cancer
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples